Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice

Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice

Introduction: During treatment with biologic agents for psoriasis (Pso) in a number of patients a failure may occur and discontinuation with transitioning to another drug or an optimization strategy, consisting in a dose-adjustment or a co-medication with a traditional systemic agent, represent two...

Full description

Bibliographic Details
Main Authors: Maria Esposito, Francesca Prignano, Franco Rongioletti, Katharina Hansel, Leonardo Bianchi, Leonardo Pescitelli, Linda Lazzeri, Federica Ricceri, Cristina Mugheddu, Mauro Bavetta, Arianna Zangrilli, Luca Bianchi, Vittorio Bini, Luca Stingeni
Format: Article
Language:English
Published: Taylor & Francis Group 2019-07-01
Series:Journal of Dermatological Treatment
Subjects:
adalimumab
anti-tnfα
psoriasis
switching
Online Access:http://dx.doi.org/10.1080/09546634.2018.1529382

Internet

http://dx.doi.org/10.1080/09546634.2018.1529382

Similar Items